September 25, 2017 4:49 PM ET

Life Sciences Tools and Services

Company Overview of Adaptive Biotechnologies Corporation

Company Overview

Adaptive Biotechnologies Corporation is engaged in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. The company offers immunosequencing platform to laboratories around the world to drive research in cancer and other immune-mediated diseases. It also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. Adaptive Biotechnologies Corporation has a strategic research agreement with Argos Therapeutics, Inc. Adaptive Biotechnologies Corporation was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in January 2012. The company w...

1551 Eastlake Avenue East

Suite 200

Seattle, WA 98102

United States

Founded in 2009

Phone:

206-659-0067

Fax:

206-659-0667

Key Executives for Adaptive Biotechnologies Corporation

Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Head of Innovation & Director
Chief Financial Officer and Director
Age: 42
Senior VP & General Counsel
Age: 58
Compensation as of Fiscal Year 2017.

Adaptive Biotechnologies Corporation Key Developments

Adaptive Biotechnologies Announces Management Changes

Adaptive Biotechnologies announced the appointment of Mr. Gene DeFelice to SVP and General Counsel, and Dr. Alexandra Snyder to Translational Medicine Lead for Adaptive Research. Both Mr. DeFelice and Dr. Snyder bring significant experience that will provide strategic and scientific guidance to the existing and future products and services that Adaptive provides. Mr. DeFelice has over 30 years of legal experience and over 20 years in healthcare, including diagnostics, biotechnology, pharmaceuticals, and medical devices. Having served as General Counsel for several public healthcare and technology companies, including a role as primary counsel at Roche Diagnostics, Mr. DeFelice will join the Executive Team to implement a legal infrastructure that prepares Adaptive for strategic decision-making to lead in the rapidly expanding market for clinical applications of NGS technologies.

Adaptive Biotechnologies Announces a Collaboration with Janssen Biotech to Use the clonoSEQ Assay to Measure Minimal Residual Disease in Ongoing and Future DARZALEX Multiple Myeloma Trials

Adaptive Biotechnologies announced it has partnered with Janssen Biotech Inc. to utilize Adaptive's NGS-based clonoSEQ Assay for measuring minimal residual disease (MRD) in patients with Multiple Myeloma (MM) who have been treated with DARZALEX (daratumumab). DARZALEX is a CD38-directed cytolytic antibody approved for the treatment of patients with relapsed or refractory MM. Under the terms of the collaboration, Adaptive will receive an undisclosed upfront technology access payment in addition to development funding and potential future milestone payments. Adaptive will be responsible for seeking regulatory approvals for and commercialization of the clonoSEQ Assay in MM. Through this collaboration, the parties will work together to demonstrate the clinical utility of monitoring MRD negativity by the clonoSEQ Assay in MM patients who have been treated with DARZALEX, and to assess the medication's ability to achieve MRD.

Heat Biologics Selects Adaptive Biotechnologies to Discover Potential Clinical Biomarkers to Advance Novel Immunotherapies

Heat Biologics Inc. announced that they have advanced their biomarker discovery collaboration with Adaptive Biotechnologies. Adaptive will use its patented immune profiling assay, immunoSEQ™, to enable an in-depth characterization of the immune response to Heat’s ImPACT and ComPACT-based immunotherapies, including HS-410, Heat’s Phase 2 product candidate for non-muscle invasive bladder cancer. The immunoSEQ Assay, when used to evaluate the mechanism of action of the ImPACT platform, provides a significant biomarker identification opportunity to better select patients and accelerate future enrollment based on immune status.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Adaptive Biotechnologies Corporation, please visit www.adaptivebiotech.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.